Over 6 million babies requiring treatment for severe jaundice each year are not receiving the treatment they need. When left untreated, severe jaundice can result in disability or death.
By designing a low-cost, high-quality phototherapy device that can be delivered through an economically self-sustaining distribution model, D-Rev aims to increase access to effective phototherapy throughout the developing world, with the end goal of reducing the number of deaths and disabilities due to untreated severe jaundice.
To measure our progress, we track three main indicators:
- the number of babies treated with Brilliance units (“Babies Treated”)
- the number of babies treated with Brilliance units who otherwise would not have received effective treatment (“Babies Otherwise”)
- the number of deaths and disabilities averted through the use of Brilliance units (“D&D Averted”)
We calculate these numbers on a per-unit basis, using an algorithm based on machine data and assumptions drawn from fieldwork and academic research, and then sum the results to determine our total estimated impact. For a detailed description of the assumptions and calculations we use, check out our step-by-step explanation.
Goal: Reduce the number of neonatal deaths and disabilities due to untreated severe jaundice
Project started: 2010
Product launched: 2012
CE Mark granted: 2013
Current status: Product is on the market. D-Rev is now scaling for broader market penetration and impact.
Product Manager: Daniel Wald